Martin Eschbach Freiburg, 20 May 2011 Parlex Conference Engaging external lawyers.

Martin EschbachFreiburg, 20 May 2011

Parlex ConferenceEngaging external lawyers

Agenda

About Novartis1.

Novartis Germany2.




4.


„Caring and Curing“ as mission statement

Net sales: USD 50,6 Billion

Employees: 119.000

Local entities: 140

Headquarter: Basel

2010 Data Novartis International


http://creative.gettyimages.com/source/Search/49','1','X122

http://creative.gettyimages.com/source/Search/21','1','V59

http://creative.gettyimages.com/source/Search/20','1','V59

4 Divisions & singular range of products

Generika – Sandoz/Hexal

Novartis Pharma

Novartis Vaccines

Consumer HealthOTC / Animal Health / CIBA VISION


Strong performance in all business areas

Sales by segment – 2010 Sales by region – 2010

Company overview

Employees 119 418

Countries 140

Headquarters Basel, Switzerland

2010 USD billion

Net sales 50.6

Net income 10.0

R&D investment 8.1

Key facts

Canada/Latin America

US

Europe

Asia/Africa/Australasia

Alcon, Inc.1

1 Regional data for Alcon, Inc. not available

Sandoz

Pharmaceuticals

Vaccines andDiagnostics

Consumer Health

Alcon, Inc.


Agenda

About Novartis1.

Novartis Germany2.




4.


About 8.000 employees* on 14 facilities in Germany

Sandoz Hexal Hauptverwaltung

Novartis Vaccines Holzkirchen

Hexal Aeropharm Produktion Rudolstadt

Sandoz Hexal Produktion Barleben bei Magdeburg

Novartis PharmaNovartis HoldingWehr

Consumer HealthTiergesundheit München

Novartis PharmaNürnberg

CIBA VISION Großwallstadt

CIBA VISIONGroßostheim

Salutas Pharma Gerlingen

Sandoz Industrial Products Frankfurt

Jenahexal Produktion Jena

Novartis Vaccines Marburg

Facility> 600 Employees

1 A Pharma Oberhaching

NeocorpWeilheim

* FTEs (=full-time employment-

equivalence)

Alcon Pharma GmbHFreiburg


Novartis-Group on the top in Germany

Gross Sales in Billion Euro*

+ 1,6 %

2009 2010

3,093.04

PFIZER

SANOFI AVENTIS

BAYER

KOHL MEDICAL AG

ROCHE

BOEHRINGER

ABBOTT

** Quelle: IMS; Total Market (DPM+Hospital)

ASTRA ZENECA

NOVARTIS

GSK

TEVA

MSD

Market Share in %** (YTD 12/2010)


People – Organizational Chart Legal & Compliance & BD & L

Country Legal Head GermanyMartin Eschbach

Head Legal, BD&L,New Products and Compliance

Martin Eschbach

LawyerE. Meuthen-Kuhnen

Lawyer J.-H. Petersen

LawyerS. Uher

LawyerA. Zierenberg

LawyerF. Zimmermann (0.5)

BD&LS. Werner

BD&LJ. Schwager

New ProductsC. Fritsch/

J. Zimmermann

Legal CoordinatorJ. Woell

Head Legal,Compliance Officer

Stefan Ibing

Head Legal,Compliance Officer

Alexander Meier

LawyerG. Keck

LawyerA. Melzer (0.7)

LawyerS. Stutz

Legal Advisor

Frank Kaul

Legal Director

GrahamWilkinson

Sandoz/Hexal Vacc. & Diagn.

= Functional report

= Direct report

Compliance K. Michel (0.5)

Ciba Vision OTC/Animal Health

PharmaConsumer Health

LawyerS. Balendran

(Name) = Assistant

Compl. OfficerU. GüllandLawyer

C. Ullmann


Agenda

About Novartis1.

Novartis Germany2.




4.


Responsibilities - departements (1/2)

• Respiratory System/Dermatology/Allergology

• Business Development & Licensing

• Controlling

• Chief Executive Officer and Managing Directors

• Communications

• Demand Managemenet

• Drug Regulatory Affairs

• Drug Safety

• Financial Reporting and Accounting

• Human Resources

• Health and Safety Executive

• Internet

• Key Account Management

• Market Access

• Medical (Medical Competence Center)

• Purchasing

• Strategic Planning and Projects

• Travel & Event Management


Responsibilities - topics (2/2)

• Tender Law

• Insurance

• Competition Law

• Anticorruption

• Labour Law

• Narcotics

• Compliance

• Data Privacy

• Industrial Property Rights

• Information Security Officer

• Anti-Trust Law

• Knowledge Management

• Social Law

• Copyright


Agenda

About Novartis1.

Novartis Germany2.




4.


Outside Counsel PanelExternal Lawyers


1. Account responsibility and global relationship

2. Engagement

3. Staffing

4. Conflicts of interest

5. Corporate citizenship

6. Relationship with responsible Novartis contacts

7. Communication with the press

8. Fees, special fee arrangements and work plans1. Fees

2. Special fee arrangements

3. Work plans and budgets

9. Disbursements

10. Bills and supporting information

External lawyers Terms of engagement (1/2)


11. Contacts with public officials

12. Security of communication and protection of information

13. Data protection, electronic communications and document retention 1. Data protection

2. Electronic communications

3. Document retention

14. Liability 1. Liability with other parties

2. Liability for undisclosed agents

3. Limitations on exclusions

15. Claims 1. Claims by us

2. Resolving claims

16. Taxes, duties and exchange controls

17. Application of laws or regulations

External lawyers Terms of engagement (2/2)


Why do we mandate external counsels?

Special know-how eg., anti-trust, M & A, labour law

Pan-European project eg., out-sourcing, IP-matters

„Bread & Butter“ contracts & business, eg. medical/study

agreements

External lawyers


External lawyers

How does success look like?

Cost/benefit analysis

Tangible value add (templates, training-material, contracts)

Trust building exercise (long term relationship)

Reasonable billing


Any questions?


Martin Eschbach Freiburg, 20 May 2011 Parlex Conference Engaging external lawyers.

Documents

Transcript of Martin Eschbach Freiburg, 20 May 2011 Parlex Conference Engaging external lawyers.